Merck KGaA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending marketing authorization of a new formulation of Rebif (interferon beta-1a) for the treatment of relapsing multiple sclerosis (MS).
From: www.pharmabiz.com
EU recommends Rebif new formulation for MS patients
Posted by Ruslan Abuzant at 9:32 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment